The QualityStocks Daily Wednesday, September 22nd, 2021

Today's Top 3 Investment Newsletters

MarketClub Analysis(MRIN) $9.2100 +61.86%

QualityStocks(MVNT) $0.0626 +52.56%

TradersPro(ACY) $42.3100 +17.20%

The QualityStocks Daily Stock List

Corvus Pharmaceuticals (CRVS)

StreetInsider, MarketBeat, StockMarketWatch, MarketClub Analysis, Zacks, BUYINS.NET, TraderPower, TopPennyStockMovers, Trades Of The Day, TradersPro, The Street, Schaeffer's, QualityStocks, PoliticsAndMyPortfolio and Penny Stock reported earlier on Corvus Pharmaceuticals (CRVS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) (FRA: C17) is a clinical stage biopharmaceutical firm that is focused on developing and commercializing immune-oncology therapies.

The firm has its headquarters in Burlingame, California and was incorporated in 2014, on January 27th by Joseph J. Buggy, Peter A. Thompson and Richard A. Miller. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector.

The company is party to a strategic collaboration with Angel Pharmaceuticals Ltd, which entails developing its pipeline of investigational medicines. The company serves consumers in the United States.

The enterprise’s product pipeline comprises of an oral small molecule A2A receptor antagonist dubbed CPI-444, which is undergoing a phase 2 clinical trial for adenosine; a covalent ITK inhibitor known as CPI-818, which is in a phase 1 clinical trial evaluating its effectiveness in treating individuals with malignant T-cell lymphomas; and an anti-CD73 monoclonal antibody dubbed CPI-006, which is undergoing a phase 3 trial for coronavirus as well as a phase 1 trial that activates different immune cells and inhibits adenosine production. The enterprise’s pre-clinical stage products include an adenosine A2B receptor antagonist dubbed CPI-935, which is indicated for fibrosis prevention; and an antibody known as CPI-182, which has been designed to block myeloid derived suppressor cells as well as neutrophil migration and function.

An Investigational New Drug application submitted by the company’s partner Angel Pharmaceuticals for their CPI-818 formulation has been accepted by the China National Medical Products Administration Center for Drug Evaluation. The success and approval of the formulation for use in treating relapsed/refractory T-cell lymphomas will benefit patients as well as bring in more revenues and investors into both companies.

Corvus Pharmaceuticals (CRVS), closed Wednesday’s trading session at $7.49, off by 12.1923%, on 29,240,632 volume. The average volume for the last 3 months is 29.241M and the stock's 52-week low/high is $1.86000001/$9.53999996.

IDW Media Holdings (IDW)

We reported earlier on IDW Media Holdings (IDW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

IDW Media Holdings Inc. (NYSE American: IDW) is a diversified media firm that is focused on television, publishing, media and entertainment distribution businesses globally.

The firm has its headquarters in Newark, New Jersey and was incorporated in 2009, on May 8th. Prior to its name change in July 2015, the firm was known as CTM (Creative Theatre Marketing) Media Holdings Inc. It markets its entertainment and media products internationally, serving consumers across the globe.

The company operates through the CTM Media group, IDW Entertainment and IDW publishing segments. The media group segment is engaged in the provision of digital distribution, right card, publishing and brochure distribution while the entertainment segment usually leverages properties into TV series development, production and distribution of original content internationally. On the other hand, the publishing segment is a graphic novel and comic book publisher that licenses and creates intellectual property as well as trading in paperback products.

The enterprise’s publications can be found in strategically located display stands, mainly at rest stops along interstates and high-traffic throughways, restaurants, attractions and hotels. Its main businesses include IDW LLC, which has grown into an integrated media firm that now includes San Diego Comic Art Gallery, Top Shelf Productions and IDW Games.

The company recently released its latest financial results, which show increases in revenue. It is currently focused on enhancing its investments in original content via partnerships with creators and authors. This move may have a positive influence not only on investments into the firm but also its consumer reach.

IDW Media Holdings (IDW), closed Wednesday’s trading session at $2.88, off by 6.4935%, on 260,325 volume. The average volume for the last 3 months is 260,226 and the stock's 52-week low/high is $2.7393999/$5.98999977.

Otonomy Inc. (OTIC)

StreetInsider, MarketBeat, StockMarketWatch, MarketClub Analysis, TraderPower, Marketbeat.com, BUYINS.NET, TradersPro, Daily Trade Alert, FreeRealTime, Investing Daily, Barchart, Schaeffer's, Wall Street Mover, Stock Market Watch, Trades Of The Day and PoliticsAndMyPortfolio reported earlier on Otonomy Inc. (OTIC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Otonomy Inc. (NASDAQ: OTIC) (FRA: 7OT) is a biotechnology firm that is focused on developing therapies for neuro-otology.

The firm has its headquarters in San Diego, California and was incorporated in 2008, on May 6th by Allen F. Ryan, Rick Friedman, Jeffrey Harris and Jay B. Lichter. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm serves consumers in California.

The company is party to a strategic collaboration with Applied Genetic Technologies Corp. which entails the development and commercialization of gene therapies for congenital hearing loss. It also has license agreements with Durect Corp. and the University of California. The company operates under the Otiprio brand.

The enterprise's product pipeline comprises of a formulation dubbed OTO-6XX, which encourages hair cell regeneration and repair and is indicated for severe hearing loss; an otoprotectant known as OTO-510 developed to prevent cisplatin-induced hearing loss; and a gene therapy dubbed OTO-825, developed to treat congenital hearing loss. It also develops a ciprofloxacin otic suspension dubbed OTIPRIO, indicated for use during tympanostomy tube placement surgery; and a dexamethasone formulation dubbed OTIVIDEX, which has concluded phase 3 clinical trials evaluating its effectiveness in treating Meniere’s disease. In addition to this, the enterprise also develops a sustained-exposure formulation dubbed OTO-413. The formulation is undergoing a phase 2 clinical trial evaluating its efficacy in treating speech-in-noise hearing difficulties and repairing cochlear synaptopathy.

The company is focused on making progress in its research programs, having recently began IND-enabling activities for its OTO-825 program. It plans to file an Investigational New Drug Application for this formulation by 2023. The move may have a positive influence on its investments and growth.

Otonomy Inc. (OTIC), closed Wednesday’s trading session at $1.76, off by 2.4931%, on 368,803 volume. The average volume for the last 3 months is 368,751 and the stock's 52-week low/high is $1.13999998/$6.9829998.

Leap Therapeutics (LPTX)

StockMarketWatch, TraderPower, QualityStocks, MarketBeat, Trades Of The Day, StreetInsider, MarketClub Analysis and BUYINS.NET reported earlier on Leap Therapeutics (LPTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Leap Therapeutics Inc. (NASDAQ: LPTX) (FRA: 5MC1) is a biopharmaceutical firm that is focused on the acquisition and development of new cancer treatments.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 2011. Prior to its name change in November 2015, the firm was known as HealthCare Pharmaceutics Inc. It serves consumers across the globe.

The company's objective is to identify translational-stage molecules in the areas of immuno-oncology and cell signaling. It develops treatments that have been designed to treat cancer patients by harnessing their immune system to attack cancer cells and impede tumor-promoting pathways.

The enterprise's product pipeline is made up of a monoclonal antibody formulation dubbed DKM-01, which impedes the DKK1 protein. The protein, which is known as the Dickkopf-related protein 1, allows tumor cells to penetrate and spread, regulates signaling pathways and suppresses an individual’s immune system from attacking tumors. The formulation is in multiple clinical trials testing its effectiveness in treating prostate cancer, gynecologic cancers, hepatobiliary cancer and esophagogastric cancer. The enterprise's other clinical studies include P103, P205, P204, P102 and P100. In addition to this, the enterprise also develops an anti-glucocorticoid-induced tumor necrosis factor receptor monoclonal antibody dubbed TRX518, which has been developed to serve as the immune system’s checkpoint agonist.

The company recently presented positive data from its phase 2 clinical trial for its DKN-01 formulation used in combination with tislelizumab to treat gastroesophageal or gastric junction cancer. These promising results signal a possible treatment for this type of cancer on the horizon, which will not only benefit patients with this ailment but also bring in more investors into the company, which will be good for its growth.

Leap Therapeutics (LPTX), closed Wednesday’s trading session at $3.25, off by 4.6921%, on 24,234,589 volume. The average volume for the last 3 months is 24.235M and the stock's 52-week low/high is $1.33000004/$3.75999999.

Jupiter Wellness Inc. (JUPW)

Tip.us, Stocks to Buy Now, SeriousTraders, QualityStocks, NetworkNewsWire, InvestorBrandNetwork, SmallCapRelations, StockWireNews, StockStreetWire, Small Cap Firm, MarketClub Analysis, Fierce Analyst, Mega Stock Alerts and Broad Street reported earlier on Jupiter Wellness Inc. (JUPW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Jupiter Wellness Inc. (NASDAQ: JUPW) is a pharmaceutical firm that is engaged in the development of CBD-based medical therapeutics and wellness products.

The firm has its headquarters in Jupiter, Florida and was incorporated in 2018, on October 24th by Brian S. John. Prior to its name change, the firm was known as CBD Brands Inc. It serves consumers across the globe.

The company is committed to helping individuals derive all of the extensive mental and physical benefits of its products.

The enterprise's product pipeline comprises of a non-prescription lotion/lip balm dubbed JW-200, which has been developed to treat symptoms of cold sores; a prescription product developed to treat burns known as JW-101; a new topical formulation which contains aspartame and CBD which has been developed to treat actinic keratosis, dermatitis and eczema dubbed JW-100 (CaniDermRX). It is also involved in the manufacture, distribution and marketing of similar consumer products, including products for dermatological treatments of inflammation and pain under the CaniDermRX brand; a skin care lotion infused with CBD under the CaniSkin brand; and a CBD-infused sunscreen which is offered under the CaniSun brand. Other CaniSun brand products include mineral-based sunscreen lotions and SPF 30 lip balm.

The firm plans to submit its JW-100 formulation for approval as an Investigational New Drug by the FDA. The formulation is indicated for the treatment of eczema, which causes the skin to become itchy, red and dry. The success of this formulation will help patients with eczema and also encourage more investments into the firm.

Jupiter Wellness Inc. (JUPW), closed Wednesday’s trading session at $1.48, up 7.2464%, on 783,918 volume. The average volume for the last 3 months is 783,918 and the stock's 52-week low/high is $1.33000004/$8.88000011.

Scientific Industries, Inc. (SCND)

QualityStocks, MarketBeat, Zacks, StocksGoneWild, Greenbackers and Epic Stock Picks reported earlier on Scientific Industries, Inc. (SCND), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Scientific Industries, Inc. designs, manufactures, and markets an array of laboratory equipment. The Company is the world leader in vortexing technologies. The Vortex-Genie Family is based upon, and originates from, the original Scientific Industries Vortex Jr. Mixer, manufactured before 1962. Scientific Industries provides benchtop laboratory equipment, customized catalyst research instruments, and bioprocessing systems and products globally. The Company is based in Bohemia, New York.

Scientific Industries is best known as the designer and manufacturer of the world-renowned Vortex-Genie® laboratory vortex mixer and shaker. This is part of a complete line of other Genie™ brand lab products. These products include microplate shakers and mixers, cell disruptor and homogenizers, magnetic stirrers, orbital shakers, rotators, rockers, and incubators.

All Genie™ products are made in the United States in its Bohemia headquarters. The Company’s products are typically used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, chemical companies, and medical device manufacturers.

In 2006, Scientific Industries diversified by acquiring Altamira Instruments. Altamira is a manufacturer of custom catalyst characterization instrumentation and bench-scale micro-reactor systems for industrial and research use globally. Moreover, in 2014, Scientific Industries expanded its benchtop laboratory equipment business with the acquisition of the Torbal product line. This is a highly reputable brand with a similar long history of quality and reliability, therefore adding a laboratory scales and pharmacy pill counters product line.

Furthermore, in 2016, Scientific Bioprocessing, Inc. was relaunched. This is a subsidiary of Scientific Industries. Scientific Bioprocessing specializes in non-invasive pH and DO monitoring in cell cultivation via its patch sensor based technology acquired by Scientific Industries in 2011.

Recently, the company announced acquisition of aquila biolabs GmbH, a privately held German technology developer of smart sensors and state-of-the-art data analytics software for bioprocessing applications under agreed upon terms. The Company believes the acquisition positions the Company to become a leading player in the bioprocessing industry.

Scientific Industries, Inc. (SCND), closed Wednesday’s trading session at $6.5, up 30%, on 6,515 volume. The average volume for the last 3 months is 6,515 and the stock's 52-week low/high is $4.8499999/$14.9899997.

Marin Software (MRIN)

MarketClub Analysis, QualityStocks, StockMarketWatch, The Street, StreetInsider, BUYINS.NET, Zacks, InvestorPlace, Marketbeat.com, PoliticsAndMyPortfolio, Schaeffer's, Seeking Alpha, MarketBeat, Kiplinger Today, Street Insider, Insider Wealth Alert, INO.com Market Report, Daily Trade Alert and MarketWatch reported earlier on Marin Software (MRIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Marin Software Inc. (NASDAQ: MRIN) (FRA: 2MAA) is a cloud-based digital advertising management firm that is engaged in the provision of enterprise marketing software for agencies and advertisers in the UK and U.S., as well as internationally.

The firm has its headquarters in San Francisco, California and was incorporated in April 2006 by Wister Walcott, Joseph Chang, Paul M. Butler and Christopher A. Lien. It operates in the communications sector, under the media industry, in the advertising and marketing sub-industry and offers its services to agencies and advertisers across the globe.

The enterprise’s objective is to give digital agencies and advertisers the power to optimize their paid marketing programs. It sells and markets its solutions to advertisers directly and via advertising agencies that utilize its platform on behalf of their consumers. The majority of the enterprise’s business activity is conducted within the geographical regions of the United States.

The company provides an ecommerce, search and social advertising platform dubbed MarinOne, which helps digital marketers make better decisions, win new consumers and convert precise audiences. This is in addition to providing Marin Social, which allows advertisers to manage their social media account advertising on platforms like Twitter, Instagram and Facebook as well as Marin Search, which helps manage advertising campaigns for agencies and advertisers.

The firm recently announced that it had enhanced its MarinOne platform, which would enable users to manage Instacart ads. This announcement pushed the company’s share prices up by 74%. The move seems to have been well received by consumers, as the share prices are still rising, which is expected to bring in more investors into the firm and in turn, boost growth.

Marin Software (MRIN), closed Wednesday’s trading session at $9.21, up 61.8629%, on 145,982,525 volume. The average volume for the last 3 months is 145.983M and the stock's 52-week low/high is $1.17999994/$27.2600002.

Aethlon Medical (AEMD)

Tip.us, Investor Ideas, QualityStocks, StockMarketWatch, Red Chip, Streetwise Reports, PennyStocks24, BUYINS.NET, MarketBeat, OTCPicks, MarketClub Analysis, FeedBlitz, TraderPower, StreetInsider, TradersPro, MicroCap Gems, AllPennyStocks, SmallCapVoice, RedChip, PennyStockRumors.net, Clutch Investments, OTC Picks, PricelessPennyStocks, Pennybuster, Stock Castle, Trading Concepts, BestStockChoice, TopPennyStockMovers, The Online Investor, DrStockPick, Faisam Trader, StockBlogs, INO Market Report, PennyOmega, Investing Futures, InvestorPlace, InvestorsUnderground, SmallCapStockPlays, SmallCap Network, Nebula Stocks, PennyTrader Publisher, WallStreet Advisors, Actual Gains and Investing Daily reported earlier on Aethlon Medical (AEMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aethlon Medical Inc. (NASDAQ: AEMD) (FRA: EJU) is a medical technology firm that is engaged in the development of products that help in diagnosing and treating organ and life threatening ailments in the U.S.

The firm has its headquarters in San Diego, California and was incorporated in May 1998 by James A. Joyce. It is a part of the scientific and technical instruments manufacturing industry and operates in the health care industry, under the medical equipment and devices sub-industry.

The company is party to a collaboration agreement with the University of Pittsburgh which entails research on neck and head cancers. It operates through the ESI and Aethlon segments. The latter segment is involved in diagnostic business activities while the former segment deals with therapeutic business activities.

The enterprise offers a platform that develops medical equipment to target the selective removal of ailment-promoting particles from an individual’s circulatory system, known as ADAPT. Its product pipeline is made of an exosomal biomarker candidate known as TauSome, which diagnoses chronic traumatic encephalopathy in people. In addition to this, the enterprise also develops a clinical-stage immunotherapeutic device known as the Aethlon Hemopurifier, which removes life-threatening viruses and exosomes from the body’s circulatory system. These exosomes aid in the progression of infectious viral pathogens like Hepatitis C and HIV as well as cancer.

The firm recently published case studies of 2 coronavirus patients who were treated with its Hemopurifier, with its CEO noting that their device may play a crucial role in filtering out exosomes, adding that their device was able to clear the SARS-CoV-2 virus from both patients’ bloodstream. The device’s success in treating both patients may bring in more investors into the firm and push share prices higher.

Aethlon Medical (AEMD), closed Wednesday’s trading session at $5.06, up 33.1579%, on 96,403,838 volume. The average volume for the last 3 months is 96.283M and the stock's 52-week low/high is $1.28999996/$12.4899997.

SolarWindow Technologies, Inc. (WNDW)

Tip.us, QualityStocks, StockOodles, InvestorPlace, NetworkNewsWire, SmallCapVoice, TopPennyStockMovers, TradersPro, PoliticsAndMyPortfolio, Market Intelligence Center Alert, Stock Gumshoe, StocksToBuyNow, Winston Small Cap, The Online Investor, AllPennyStocks and Wealth Insider Alert reported earlier on SolarWindow Technologies, Inc. (WNDW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SolarWindow Technologies, Inc. is a developer of next generation, transparent, electricity-generating SolarWindow™ coatings. The Company is a developer of electricity-generating windows for tall towers and skyscrapers. SolarWindow™ utilizes organic materials dissolved into liquid, best for low-cost high-output manufacturing. SolarWindow Technologies is headquartered in Columbia, Maryland.

SolarWindow™ systems can undergo installation on the readily-available sizeable window glass surfaces on tall towers and skyscrapers. SolarWindow™ can be applied to the sides of tall towers, generating electricity using natural, shaded, and artificial light. The coatings produce electricity on see-through glass and flexible plastics with colored tints popular to skyscraper glass. Upon application to glass or plastics, the coatings convert passive windows and other materials into electricity generators under natural, artificial, low, shaded, and reflected light conditions.

SolarWindow™ technology has been independently validated to generate 50-times the power of a conventional rooftop solar system. Moreover, it realizes a one-year payback when modeled on a 50-story building. SolarWindow Technologies’ latest products will be engineered as transparent, tinted, flexible veneers, which installers can apply directly over top of existing windows on tall towers and skyscrapers. This expanded product line extends the Company’s market reach beyond new and replacement installations, to include windows now installed on the estimated five million commercial buildings built in the U.S. alone.  

SolarWindow Technologies is expanding product development to include applying its electricity-generating coatings onto flexible glass – as thin as a business card (only 0.1-millimeter-thick), which is flexible enough to be bent without breaking or cracking.

In November, SolarWindow Technologies announced the completion of a $25 million equity financing. Kalen Capital Corporation (KCC), the family office of Mr. Harmel S. Rayat, Founder and Chairman of the company, invested roughly $24.9 million in this round.

Mr. John Conklin, President and Chief Executive Officer of SolarWindow Technologies, said, “This capital infusion marks a historical inflection point for SolarWindow and our nearly 15,000 shareholders. With this capital in hand and a decade of research and development behind us, we can now purchase equipment and hire personnel required for manufacturing of electricity-generating glass, a brand-new form of electrification.”

SolarWindow Technologies, Inc. (WNDW), closed Wednesday’s trading session at $5.99, up 33.2592%, on 330,910 volume. The average volume for the last 3 months is 329,710 and the stock's 52-week low/high is $2.83999991/$39.2000007.

Movement Industries (MVNT)

We reported earlier on Movement Industries (MVNT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Movement Industries Corporation (OTC: MVNT) is engaged in the provision of fabrication and CNC (computer numerically controlled) machining services to energy companies.

The firm has its headquarters in Houston, Texas and was founded in 1996, on October 4 by Gerard Dab. It operates in the technology sector, under the software and tech services industry, in the software sub-industry. Prior to its name change in August 2019, the firm was known as Visual Healthcare Corp. The firm is a subsidiary of LTN Capital Ventures LLC.

The company’s executive management team has more than 5 decades of experience in the international energy market. Its growth strategy is made up of the acquisition of complementary business units as well as services provided to existing consumers.

The enterprise invests in emerging firms in the industrial manufacturing, renewables, gas and oil and energy sectors. It provides valves to the oil and gas industry, as well as communication systems, control systems, welding fabrication, laser cutting, plasma, waterjet, CNC machining, wellhead control panels, tanks, pumps and actuators. In addition to this, the firm is also involved in the development and marketing of medical information systems. These systems help integrate clinical data entries, results reported, nurses and doctor’s notes and physician order entries.

The company’s CEO recently provided an update to highlight its accomplishments, noting that the company was focused on attaining its goals of maximizing profit and revenue growth and increasing shareholder value. This will be beneficial to both the company’s stakeholders and its shares.

Movement Industries (MVNT), closed Wednesday’s trading session at $0.06255, up 52.561%, on 1,883,069 volume. The average volume for the last 3 months is 1.883M and the stock's 52-week low/high is $0.0115/$0.119900003.

Royale Energy,  Inc. (ROYL)

QualityStocks, MarketBeat, All about trends, Lebed.biz, Greenbackers, OTCPicks, PennyToBuck, PennyOmega, StockHotTips, SmarTrend Newsletters, CRWEWallStreet, CRWEPicks, CRWEFinance, BestOtc, Wall Street Resources, DrStockPick, SmallCapVoice, Daily Markets, OTC Picks, FeedBlitz, SmallCapInvestor.com, Turn Key Oil, TradingMarkets, StreetInsider, MicrocapVoice, The Street, Street Insider, Stock Analyzer, Dynamic Wealth Report, Oakshire Financial, PennyTrader Publisher, Hit and Run Candle Sticks, Investing Futures, Jason Bond, PennyStockDD, Penny Stock Rumble, Marketbeat.com, Microcapmillionaires, WealthMakers and FNNO Newsletters reported earlier on Royale Energy,  Inc. (ROYL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Royale Energy, Inc. concentrates on the acquisition, development, and marketing of natural gas and oil. It owns and operates wells in the Sacramento and San Joaquin basins in California and has royalty interests in Alaska.  The Company engages in the production and sale of natural gas;  the acquisition of oil and gas lease interests and proved reserves;  the drilling of exploratory and development wells; and the sale of fractional working interests in wells to undergo drilling. Royale Energy has its corporate office in El Cajon, California.   

Royale Energy has properties encompassing more than 20,000 acres in California and nine 3D seismic surveys in the Sacramento Basin. Currently, the Company operates greater than 60 natural gas wells. It owns interests in 12 natural gas fields in California. 

Royale Energy’s North Arbuckle is in Colusa County in the Sacramento Basin. At present, this is the most active area for the Company. It has 10 producing natural gas wells that have produced over 5 billion cubic ft. 

Royale has acquired greater than 96,000 acres on the Alaskan North Slope. The acreage spans over 88 miles east and west of the Trans-Alaska pipeline route.

The Company has its Lonestar Field. It includes in excess of 1,000 acres. The Lonestar Field has produced more than five billion cubic ft. of gas from five separate Forbes sandstone reservoirs. The Lonestar Field includes the Goddard 7-1 Well; the Goddard #2 and Goddard #3 (offset wells to the Goddard 7-1); and the Magnum Well.

Additionally,  Royale’s Victor Ranch Field is in Tehama County, in the Northern Sacramento Basin. This field has been producing natural gas for the Company since it drilled its first well there in 1993.

Royale Energy has an agreement with a major independent exploration and development company to expand its joint development agreement in the Sacramento Basin of Northern California. The expanded arrangement covers about 1,900 acres in the Rio Vista Gas Field. Royale will target the Capay and Martinez sands.  

Royale Energy and Matrix Oil Management Corporation jointly announced earlier in 2018 the closing and completion of the merger between Royale and Matrix. The merger transaction was approved by the Matrix and Royale Energy shareholders on November 16, 2017. It closed after the companies received the consent of Matrix’s lender, Arena Limited SPV, LLC.

Royale Energy and CIC Partners have created a new Joint Venture (JV) named RMX Resources. This JV will fund, drill and produce oil at the prolific Sansinena Oil Field. CIC contributed an aggregate of $25,000,000 in cash in exchange for an 80 percent equity interest. Royale Energy received a 20 percent equity interest plus working capital in exchange for contribution of Sansinena and surrounding area assets. CIC is a Dallas-based private equity organization.

Last month, Royale Energy announced the appointment of Board Director Mr. Rod Eson as Chief Executive Officer (CEO) effective (immediately). Before accepting the CEO responsibilities at Royale Energy, Mr. Eson served as the CEO of Foothill Energy LLC, a California-focused company he founded in 2004.

Royale Energy,  Inc. (ROYL), closed Wednesday’s trading session at $0.0957, up 91.4%, on 137,414 volume. The average volume for the last 3 months is 137,414 and the stock's 52-week low/high is $0.0401/$0.201000005.

RenovoRx Inc. (RNXT)

We reported earlier on RenovoRx Inc. (RNXT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

RenovoRx (NASDAQ: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, has closed its underwritten initial public offering of 1,850,000 units at a public offering price per unit of $9.00. According to the update, RenovoRx offered all of the units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock.

The warrants have a $10.80 exercise price per share and are exercisable for a period of five years after the issuance date. In addition, RenovoRx granted the underwriters a 45-day option to purchase up to an additional 277,500 shares of its common stock, and/or warrants to purchase up to an additional 277,500 shares of its common stock, at the initial public offering price, less underwriting discounts and commissions. RenovoRx’s common stock was approved for listing on The Nasdaq Capital Market under the ticker symbol RNXT in connection with the offering, which closed on Aug. 30, 2021. Roth Capital Partners acted as sole book-running manager for the offering.

To view the full press release, visit https://ibn.fm/eFfwg

RenovoRx, a biopharmaceutical company headquartered in Silicon Valley, California, has developed a therapy platform targeting difficult-to-treat tumors. Targeted therapy via the proprietary RenovoRx Trans-Arterial Micro-Perfusion (“RenovoTAMP”) platform safely and without transmission to non-targeted areas, is the primary focus.

RenovoRx’s portfolio includes seven U.S. patents for its technology. The company also has secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine including pancreatic and bile duct cancers. The RenovoTAMP therapy is being studied in the phase III TIGeR-PaC trial for the treatment of locally advanced pancreatic cancer. For more information, please visit www.RenovoRX.com.

RenovoRx Inc. (RNXT), closed Wednesday’s trading session at $7.34, off by 2.1333%, on 436,870 volume. The average volume for the last 3 months is 436,870 and the stock's 52-week low/high is $6.65999984/$16.7399997.

The QualityStocks Company Corner

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF)

The QualityStocks Daily Newsletter would like to spotlight LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF).

Virtual Investor Conferences, the leading proprietary investor conference series, announced the presentations from the September 21st Financial Services Virtual investor Conference are now available for on-demand viewing. LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) was noted today as among the participants https://bit.ly/3hTIrAl. This virtual event showcased live executive presentations and interactive discussions focused on publicly traded community banks and fintech companies. The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company's "virtual trade booth".

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption.

LQwD FinTech’s mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling of bitcoin. LQwD is also securing a substantial position in bitcoin as an operating asset and will use its holdings to establish nodes and payment channels on the Lightning Network.

The Lightning Network is a second-layer protocol, sitting above the bitcoin blockchain, intended to facilitate faster micro-transactions and lower fees on bitcoin transactions, thus allowing mass adoption of bitcoin.

LQwD expects the Lightning Network to eclipse the patchwork of legacy financial networks that are used to move value today. The company’s software will make migration from legacy networks onto the Lightning Network easy and seamless. By onboarding more financial service providers, LQwD intends to grow the value of the Lightning Network.

The company, formerly known as Interlapse Technologies Corp., is harnessing new payment rails built on top of the bitcoin blockchain that are capable of beyond visa-level transaction volumes and backed by bitcoin, the strongest and most well-known cryptocurrency. These new rails, enabled by the Bitcoin Lightning Network, open a vast opportunity and market segment for digital payments and financial services on a global scale. LQwD aims to leverage its position as a public company to enhance trust in its products and services, and leverage its shares as currency for acquisitions, roll-up and growth, as well as to attract and retain top industry talent.

Product

The Lightning Network is a solution to massively scale the use of bitcoin for microtransactions globally, dramatically improving upon fees, as well as providing instant settlement times. The Lightning Network has experienced explosive growth and is expected to continue with the trend as usage increases. Well-known companies, such as Twitter and Square, have expressed their enthusiasm to incorporate Lightning Network into their platforms. The Lightning Network is scalable, global, open, inclusive, permissionless and decentralized. It is made up of nodes connected via payment channels, and enables off-chain, instantaneous and cheap payments at scale.

Upon launch of LQwD’s Lightning Network platform-as-a-service, users will be able to leverage the Lightning Network infrastructure to send payments instantly, securely and inexpensively anywhere in the world. Companies and service providers will be able to conduct Lightning Network transactions in bitcoin by integrating LQwD’s infrastructure with their business or web property. Connected businesses will be able to easily deploy, monitor and manage LQwD’s Lightning Network nodes with no or low-level technical knowledge required. The company fully expects Lightning Network to be a force for global change and to become the monetary exchange network of the future.

The Lightning Network, which is already built, functioning and growing, will advance bitcoin from a store-of-value to a global monetary network through payment utility. The company expects the Lightning Network will propel the growing number of active blockchain wallets to new heights, by increasing bitcoin’s scalability and lowering its fees for users. For coming generations, everything from wealth to experiences will be acquired and transacted virtually, and LQwD sees the Lightning Network as an enabling technology that can bring bitcoin to hundreds of millions of new users across the globe.

Market Outlook

Forbes in August 2021 noted that “private investors are funding companies that are building the infrastructure that will support future growth of crypto and digital assets,” and called public companies building cryptocurrency infrastructure “the hottest part of the crypto market.” While the first wave of investor interest in crypto firms was directed at companies catering to retail investors, investors have now shifted their attention to infrastructure builders, like LQwD FinTech. Forbes did not put an estimated value on the crypto infrastructure market but pointed out that large-scale adoption of cryptocurrencies will only happen when infrastructure is in place to support it. The larger digital payments market, of which crypto payments are a small fraction, is growing at more than 14 percent annually and is forecast to hit $154 billion by 2025.

Management Team

Shone Anstey is co-founder, chairman and CEO at LQwD FinTech. He has 20 years of experience in building complex technologies and has acted as technology lead for an industrial bitcoin mine and bitcoin mining pool. He is a Certified Cryptocurrency Investigator, and an advisor to the British Columbia Securities Commission. He is also co-founder of BIGG Digital Assets (OTCQX: BBKCF) and took that company public in 2017.

Barry MacNeil is CFO at LQwD FinTech. He is a member of the Chartered Professional Accountants of British Columbia and has more than 30 years of management and accounting experience with public companies and in private practice. His previous positions include director of both public companies and nonprofits, as well as Chief Financial Officer and Corporate Controller.

Albert Szmigielski is co-founder and CTO at LQwD FinTech. He was formerly the Head of Research and Chief Blockchain Engineer at Blockchain Intelligence Group and VP Research at CipherTrace. He holds a B.Sc. in Computing Science from Simon Fraser University, and a Master of Science in Digital Currencies and Blockchain Technologies from the University of Nicosia, Cyprus.

LQwD FinTech Corp. (LQWDF), closed Wednesday’s trading session at $0.3324, up 9.3457%, on 2,022 volume. The average volume for the last 3 months is 2,022 and the stock's 52-week low/high is $0.088299997/$4.00.

Recent News

Green Hygienics Holdings Inc. (OTCQB: GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (OTCQB: GRYN).

Green Hygienics Holdings (OTCQB: GRYN), an innovative, technology-driven enterprise focused on the high-standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids, announced the offering of a green bond exclusively in Europe (the “offering”) in the principal amount of US$100 million. According to the update, the offering is issued for a five-year term with a yield of 7.25%, is not convertible, does not include warrants and, subject to customary conditions, is expected to close on or around Nov. 30, 2021. Green Hygienics has engaged Dechert LLP (Luxembourg), a leading global law firm with 22 offices around the world. Dechert advises on matters and transactions of the greatest complexity, bringing energy creativity and efficient management of legal issues to deliver commercial and practical advice for clients. The company intends to list the green bond on the Luxembourg Stock Exchange (“LuxSE”), a pioneer in green finance. To view the full press release, visit https://ibn.fm/odo1a

Green Hygienics Holdings Inc. (OTCQB: GRYN) is a California-based innovative technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids.

The company aims to be a leader in compliance and capabilities in the hemp and cannabinoid supply marketplace. By leveraging state of the art technologies, the company intends to open up a whole new world of novel cannabinoids and targeted bio-delivery technologies never before explored, solving the issues of stability, pharmacokinetics, biological tissue penetration and bioavailability.

Dedicated to creating the hemp industry’s safest and finest quality products, the company will be uniquely positioned to deliver product efficacy and supply chain solutions to consumers, as well as to leverage these within its own products and brand portfolio.

USDA Organic Certification and FDA Registration

On August 26, 2020, Green Hygienics registered with the U.S. Food and Drug Administration pursuant to the Federal Food Drug and Cosmetic Act, as amended by the Bioterrorism Act of 2002. This registration strengthens the company’s core mission to provide product efficacy to the pharmaceutical industry and consumers alike.

On September 30, 2020, Green Hygienics was granted USDA Organic Certification (7 CFR Part 205) for the cultivation and post-harvest processing of industrial hemp by the California Certified Organic Farmers for its Sol Valley Ranch property. This certification further enables the company to supply certified organic hemp products to national and international markets.

Market Opportunity

Green Hygienics is focused on finding, acquiring and developing strategically positioned businesses, as well as the best innovations within the hemp industry – a fast-progressing market with remarkable opportunities for growth. The industrial hemp market is expected to reach $5.33 billion in 2020 and is projected to rise to $15.26 billion by 2027, achieving a CAGR of 15.8%, per Grand View Research.

Capital Structure

GRYN has less than 42 million shares outstanding, fully diluted. The company has just 7.2 million common shares in float and boasts a balance sheet with no toxic debt or overhang.

Key Management

Dr. Levan Darjania serves as the company’s Chief Science Officer. Darjania has over 26 years of experience in biotechnology and pharmaceutical drug development. His research and development experience has led him to develop many in-house and collaborative R&D programs over the course of his career.

Kyle MacKinnon serves as GRYN’s Chief Operating Officer. He has extensive knowledge in cannabis processing and was previously the Business Development Manager of Advanced Extraction Systems Inc., a leader in CO2 Supercritical Fluid Extraction. MacKinnon brings over 20 years of sales and management experience to the company.

Ronald Loudoun is the President, CEO, Secretary and Director of Green Hygienics. He received an undergraduate business degree from the British Columbia Institute of Technology. Before joining Green Hygienics, he was the founder and a director of renewable energy firm Archer CleanTech Inc.

Jerry Halamuda is the Senior Vice President of Business Development of the company’s Agriculture Division. He has an extensive career working in the agriculture and horticulture industry. Halamuda has founded, managed and operated multiple successful companies, including Color Spot Nurseries.

John Gildea is GRYN’s Senior Vice President of Corporate Development. He has over 20 years of experience working within the private and public markets. His expertise includes negotiating and structuring private and public financing and mergers. During the course of his work, Gildea has established trusted relationships with a network of equity and capital partners.

 

Green Hygienics Holdings Inc. (OTCQB: GRYN), closed Wednesday’s trading session at $1.7, even for the day, on 22,969 volume. The average volume for the last 3 months is 22,969 and the stock's 52-week low/high is $0.457549989/$2.45000004.

Recent News

Sugarmade, Inc. (OTC: SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (OTC: SGMD).

  • Nug Avenue has picked up more than 10,000 new unique members as of the end of June, significantly exceeding initial projections
  • Sugarmade has opened an escrow account for the purpose of acquiring property in California to be used for delivery hub
  • SGMD has taken steps toward making an offer on licenses for the state of Oregon

A growing cannabis delivery service, new commercial licenses and expansion into Oregon were highlights of a recent update provided by Sugarmade (OTC: SGMD). The emerging leader in the vertically integrated California cannabis marketplace released an update for current and prospective shareholders containing details of these key milestones in the company’s strategic plan (https://cnw.fm/Yyl1Q).

Sugarmade, Inc. (OTC: SGMD) is a product and brand marketing company investing in operations and technologies with disruptive potential. The company is focused on collaborating with real people in real-time to identify the emerging desires and behaviors poised to unlock new opportunities and pathways for growth. Sugarmade seeks to redefine the marketplace by nurturing an innovative and compelling relationship between brand, botany and business – resulting in both undeniable consumer value and an intriguing cross-pollination of revenue sources.

The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business.

Brand Portfolio

Sugarmade has investments in a number of subsidiaries with active operations in the California cannabis sector. These include:

  • NUG Avenue – Sugarmade owns a 70% stake in NUG Avenue, a cannabis delivery service based in Southern California providing hand-selected top-shelf products from Stiiizy, Kanha, PlugPlay and more.
  • BudCars – Sugarmade is an investor in cannabis delivery service of BudCars’ first operating location in Sacramento, California. BudCars is an online-shopping experience designed to provide new customers with an easy way to discover and order cannabis products within minutes.

Acquisition of Lemon Glow Company

On May 17, 2021, Sugarmade took a major step toward closing the loop on what its management team believes to be one of the most promising vertically integrated cannabis models in the thriving California market when it announced the signing of a definitive agreement for its acquisition of Lemon Glow Company Inc.

The Lemon Glow acquisition includes 640 acres of property, 32 of which have already been designated for outdoor cannabis cultivation. Per the company’s news release, the annual potential cultivation yield at the property is estimated to be approximately 4,000 pounds of dry trimmed cannabis flower per acre per year, which represents approximately 128,000 pounds, or 64 tons, of dry trimmed cannabis flower per year in total.

Notably, Sugarmade also benefits from the acquisition in terms of team capital, as Lemon Glow executive team members will stay on and become the core management team at the cannabis cultivation site, granting the operation over 30 years of cannabis cultivation experience.

“The Lemon Glow team are tremendous additions to the Sugarmade team,” Jimmy Chan, CEO of Sugarmade, commented in announcing the definitive agreement. “They have vast experience and established skills, as well as intricate knowledge of the property and its local grow context. That’s an enormous added value proposition in this deal. We look forward to bringing them on board, ramping up operations at the property, and taking key steps toward delivering on the promise of Sugarmade’s farm-to-door vision.”

Market Opportunity

The California cannabis industry has continued to record tremendous growth since voters approved a measure to legalize recreational use of the plant in 2016. According to data from MJBizDaily, California’s legal market hit $4.4 billion in sales in 2020, up from $2.8 billion in 2019 and $1.4 billion in 2018.

Those figures highlight California’s status as the largest legal cannabis market in the world. With roughly 28 million residents over the age of 21, California is more than twice the combined size of the four states (Arizona, New Jersey, Montana and North Dakota) that legalized cannabis in 2020.

The COVID-19 pandemic was a key driver in the growth of cannabis delivery services throughout the state in 2020. One California cannabis delivery firm reported a 60% increase in new delivery customer sign-ups in the 30 days following the March 13, 2020, declaration of a national emergency. As a result of this boom, tech companies in cannabis ecommerce were able to dramatically increase their market share.
Sugarmade’s continued efforts to develop a farm-to-door vertically integrated cannabis business position it to capitalize on these trends as the California cannabis industry continues to expand moving forward.

Management

Jimmy Chan is the CEO of Sugarmade. He is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Sugarmade, Inc. (OTC: SGMD), closed Wednesday’s trading session at $0.0019, up 18.75%, on 54,325,116 volume. The average volume for the last 3 months is 54.325M and the stock's 52-week low/high is $0.000699999/$0.019999999.

Recent News

American Cannabis Partners

The QualityStocks Daily Newsletter would like to spotlight American Cannabis Partners.

Privately owned American Cannabis Partners (“‘ACP”), a multistate operator creating a sustainable Jamaican cannabis experience, has created a cash flow positive business model that protects shareholders and the company regardless of the fluctuations in the industry. ACP’s CEO, Stephen Jordan worked in the cannabis business for three years in Jamaica. He brought those relationships, and employees with 30-40 years of experience in cultivation, back with him to California when recreational cannabis became legal in 2018. The company currently operates in Northern California and Michigan with plans to expand into a third state within the next year.

American Cannabis Partners (ACP) is a multi-state cannabis company with 560,000 square feet of licensed canopy space for cultivation and one retail license. The company is nationally headquartered in Trinity County of Northern California’s Emerald Triangle.

ACP is focused on three complementary business segments: real estate, acquisition & development of proprietary assets, and ongoing cultivation operations. Led by a seasoned management team with 30+ years of canna-business experience, ACP’s strategy is to capture opportunities in real estate and licensing in states that have recently passed cannabis legalization legislation, thereby equipping the company to capitalize on Federal interstate commerce opportunities.

Through its current cultivation operations, ACP supplies approximately 80% of its whole flower products for manufacturing, distribution and retail licenses. With the remaining 20%, the company supplies its proprietary strains to select California distributors and its own Michigan retail location under its exclusive in-house brand, ZÜK.

History of American Cannabis Partners

In 2014, Stephen Jordan, President of ACP, took on the Director of Operations position for a U.S.-based company operating in the Jamaican cannabis space. Over the course of his three-year tenure in this role, Jordan developed a number of relationships that would help serve as the basis of American Cannabis Partners.

One such relationship was with Junior Gordon, a cultivation lead grower from Jamaica’s Westmoreland Parish. Jordan immediately saw the value of Gordon’s unique skillset and credentials, and Gordon recognized Jordan’s heartfelt vision of bringing Jamaican culture to the rapidly developing U.S. cannabis space.

Guided by that mission, ACP’s unchanging goal is to improve the lives of individuals through cannabis and business.

Current Operations

Since its founding in 2018, privately-owned American Cannabis Partners has established a foothold in two key U.S. cannabis markets – California and Michigan. In total, the company has acquired 12 cannabis licenses, including 20,000 sq. ft. of cultivation licenses in California and 540,000 sq. ft. of cultivation licenses & one retail license in Michigan.

ACP’s IP portfolio features three proprietary strains sold exclusively through the company’s wholly owned ZÜK brand, as well as proprietary data collection and mining systems supporting its cultivation and retail operations.

Plans for Expansion

American Cannabis Partners is pursuing additional growth in the cannabis sector through multiple planned initiatives. These include:

  • Submitting applications for additional cultivation licenses at the company’s Trinity County, California, location;
  • Planning land acquisition and project development strategies for expanding operations to its third U.S. state beginning in the second quarter of 2022; and
  • Planning land acquisition and project development strategies for expanding operations to its fourth U.S. state beginning in the second quarter of 2024.

ACP is currently exploring expansion opportunities through partnerships and joint ventures in New Jersey, New York, Virginia, Nevada, Arizona, Missouri and Massachusetts.

Management Team

Stephen Jordan is the CEO of American Cannabis Partners. He is focused on the first and last steps of legal cannabis – cultivation and retail. To date, Mr. Jordan has provided the company with ownership of 12 licenses, three proprietary cannabis strains and multiple real estate assets. His background in cannabis operations and financial strategies has guided American Cannabis Partners’ efforts to produce consistently high-quality product for both the medical and recreational segments. Mr. Jordan has operated under cultivation, manufacturing, distribution, medical research (Univ. of West Indies), retail and exportation licenses in multiple countries, further strengthening his network within the cannabis industry.

Gary Coltek is the company’s Chief Operating Officer. He has credentials based in the culinary, hospitality and sustainability industries spanning over 40 years, including taking three companies public. Mr. Coltek has held management positions internationally with Ritz Carlton, Four Seasons, Trump Hospitality, Phymatrix and International Oncology Network. For 17 years, he was the founding member and partner of a private boutique consulting firm. He is currently a guest speaker and visiting professor at universities in Israel, China, Italy, the Netherlands and Peru, covering topics that include culinary sustainability, sustainable cannabis farming, organic sustainable farming and cannabis clinical studies.

Scot C. Crow is the Lead Corporate Counsel for American Cannabis Partners. He has extensive experience in corporate mergers & acquisitions and tax law. His clients rely on him to advise them with respect to their complex financial transactions and provide outside general counsel. Mr. Crow provides his clients proactive advice with respect to sensitive management matters, litigation management, day to day transactional needs and objective assessments for the development of successful business strategies. His experience includes serving as lead counsel for numerous mergers & acquisitions, private equity investments, private offerings, venture capital financings, mezzanine debt offerings, divestures and other related transactions, with an emphasis in the legalized marijuana segment.

Jacob Frenkel is the company’s Lead Compliance Counsel. He is the current Chair of Dickinson Wright’s Government Investigations and Securities Enforcement Practice. Mr. Frenkel’s solutions-minded approach to issues has earned him a reputation as an aggressive, tenacious, creative and proactive defense lawyer and litigator. After 14 years as a Senior Counsel in the SEC’s Division of Enforcement, U.S. federal criminal prosecutor and New Orleans Assistant District Attorney, Mr. Frenkel has practiced in the private sector for 20 years. His unique mix of corporate transactional, litigation and investigations defense clients extend well beyond the cannabis industry and cover a wide range of industries worldwide.

Junior Gordon is the Director of Cultivation for American Cannabis Partners. With 30 years of international cannabis cultivation experience in both the Caribbean and United States, Mr. Gordon is recognized as one of the top growers in the world. His skills span both controlled indoor and large volume outdoor harvest programs, giving him proficiency in nursery, propagation and indoor & outdoor grow strategies. As a winner of High Times and other notable Cannabis Cups, his focus is on connecting the dots between propagation, soil, irrigation, planting, harvesting, curing, processing and inventory control, bringing Jamaican cannabis cultivation best practices to American Cannabis Partners’ operations.

Recent News

chart

Nemaura Medical Inc. (NASDAQ: NMRD)

The QualityStocks Daily Newsletter would like to spotlight Nemaura Medical Inc. (NASDAQ: NMRD).

via InvestorWire -- Nemaura Medical Inc. (NASDAQ: NMRD)  announced its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Healthcare Technologies Spearheading Modern Medicine Movement, Providing Hope to Throttle Diabetes, Obesity,” please visit: https://nnw.fm/aKQpJ. Exorbitant costs underscored by byzantine processes plague today’s healthcare systems, creating an $8.45 trillion global healthcare market in 2018, which represents about 10% of GDP in developed countries. Safe to say, the industry is looking for solutions, particularly more efficient ones that improve health outcomes and lower direct and indirect costs. The answer is found in technology, with healthtech (healthcare technology) and medtech (medical technology) buzzwords speaking to leveraging next-generation innovation in a bid to flatten the healthcare spending curve. New applications are being launched daily, and uptake is accelerating, fanned by the COVID-19 pandemic that bolstered adoption of self-diagnostic and remote solutions that have been embraced by health insurers and individuals alike. Some companies, such as Nemaura Medical Inc. (NASDAQ: NMRD ), are specializing in certain areas of unmet medical need, such as diabetes and obesity.

Nemaura Medical Inc. (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Its flagship product, sugarBEAT®, is a wearable, non-invasive and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and prediabetes manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading.

sugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with a smartphone app displaying glucose readings at five-minute intervals for periods of up to 24 hours. One of the great advantages of the product, apart from the fact that users no longer need to draw blood samples or prick their fingers, is that a person can wear the CGM patch on whatever day they choose. Existing CGM devices must be implanted under the skin. Wearable disposability is a unique feature of sugarBEAT and a world first, opening up vast potential for changing the way people manage their chronic disease conditions. sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union as a Class 2b Medical Device. The company submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration in 2020 which is currently under review.

Founded in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and well-being. Nemaura’s skin surface blood monitoring technology has allowed the company to create additional products, which are in the pipeline, such as Lactate Monitoring.

Technologies

Digital Solutions for Weight Loss and Potential Reversal of Type 2 Diabetes

This is a digital program that comes with more than a decade of clinical evidence demonstrating excellent efficacy. The company has combined this with its glucose-monitoring platform to bring a product to market to help people with diabetes manage their condition and potentially reverse Type 2 diabetes.

Glucose Monitoring Solutions for Diabetes Prevention and Reversal

Over 420 million people worldwide are living with diabetes, and prediabetes cases total almost three times that number. Undoubtedly, diabetes is an urgent global health crisis. Combining clinical research with patient-friendly technology, Nemaura’s sugarBEAT product delivers a non-invasive, affordable and flexible method of blood glucose tracking for improved diabetes management.

Continuous Lactate Monitoring for Athletic Performance (Non-Medical)

Lactic acid is a key performance indicator for the body and a guide to how well muscles react to long term exertion and recovery. Well-trained athletes and those who regularly engage in sports are very efficient at faster lactate ‘recycling’ for extra energy (ATP). Nemaura expects to launch its lactate sensor to the sports and personal training market in 2022.

Continuous Lactate Monitoring in Disease State (Medical)

An increase in blood lactate levels is also a marker of critical disease states. Recent publications have indicated the presence of elevated lactate levels in patients with COVID-19 infection. Nemaura has developed a lactate sensor that is being integrated into the company’s platform, which will be submitted for regulatory clearance upon completion of requisite clinical studies.

Continuous Temperature Monitoring for Viral Infection Detection and Disease Progression

A person’s body temperature says a lot about their health. Several diseases, including COVID-19, are characterized by an increase in body temperature, so temperature monitoring is a vital tool in the detection, diagnosis and prevention of the spread of disease. Nemaura is expecting to submit this adaptation of the device for regulatory clearance in 2022.

Market Opportunity

Obesity and diabetes are two of the major drivers of the current chronic disease epidemic. According to the International Diabetes Federation, there are more than 463 million people living with diabetes worldwide. In the U.S., about 28,000 people are diagnosed with diabetes every week, and more than 34 million suffer from diabetes. Another 88 million Americans have prediabetes. Other industrialized countries show similar numbers based on their populations. In the U.K., 4.8 million people have diabetes, with another diagnosed every two minutes. In Germany, 9.5 million have diabetes, with almost half estimated to be undiagnosed and so at greater risk.

On average, employers and insurers spend more than $9,000 annually on health care for an employee with diabetes, compared to $1,600 annually for a healthy employee. In the U.S. alone, more than $760 billion was spent on diabetes-related health care expenditures during 2019. Nemaura is positioned at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications forecast to hit $60 billion by 2023.

Management Team

Dr. Faz Chowdhury has been CEO and chairman of the board of Nemaura Medical since 2013. He has more than 20 years of experience in the pharmaceutical and medical devices industry, taking products from concept to commercial launch. He is sole inventor on more than 100 granted and pending patents and has authored textbook chapters on nano-biosciences for Wiley and Elsevier. He holds a master’s degree in microsystems and nanotechnology from Cranfield University, and a doctorate from the University of Oxford in nano-medicine and drug delivery.

Justin Mclarney is CFO at Nemaura. He most recently was the Senior Director, International Finance at Lands’ End Inc. He also worked for Office Depot as Senior Director of Finance for the largest business unit within the European group. Prior to that, he spent more than 10 years in practice, the majority of which was with Ernst & Young LLP.

Dr. Fred Schaebsdau is Vice President of Strategy & Strategic Alliances at Nemaura. He has more than 15 years of executive experience in the CGM, blood glucose monitoring and insulin delivery industries, including time with Abbott Diabetes Care, as General Manager of Dexcom Germany and at Roche Diabetes Care, where he was Senior Vice-President, Head of Global Strategy and Business Development. The firm he founded is the exclusive distributor in Europe, the Middle East and Africa of UniStrip®, the world’s first generic blood glucose test strip. He is licensed to practice medicine in the U.S. and Germany.

David Scott is Director of Commercial Development and Licensing at Nemaura. He is a trained chemist with over 35 years of experience in the pharmaceutical industry, including deal brokering, marketing, strategic planning, finance, business development and acquisitions. He has also provided licensing training for a number of multinational pharma companies and training organizations and is the author of best-selling report Scrip’s Practical Guide to Pharmaceutical Licensing.

Nemaura Medical Inc. (NASDAQ: NMRD), closed Wednesday’s trading session at $5.94, off by 3.7277%, on 39,432 volume. The average volume for the last 3 months is 39,432 and the stock's 52-week low/high is $3.11730003/$17.3999996.

Recent News

Vivos Therapeutics Inc. (NASDAQ: VVOS)

The QualityStocks Daily Newsletter would like to spotlight Vivos Therapeutics Inc. (NASDAQ: VVOS).

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Healthcare Small Cap Conference at 2:20 pm ET on Wednesday, Sept. 29, 2021. The event is scheduled to take place from Sept. 29-30, 2021. Investors interested in joining the Vivos presentation should visit https://ibn.fm/JFY3h to register for a free spectator pass. A replay of the presentation will be available for view following the presentation on Vivos’ website. To view the full press release, visit https://ibn.fm/9OTzy

Headquartered in Denver, Colorado, Vivos Therapeutics Inc. (NASDAQ: VVOS) is an emerging global leader in the treatment of mild-to-moderate obstructive sleep apnea (OSA), a debilitating condition affecting nearly 1 billion people worldwide. The company utilizes proprietary, ground-breaking technology, a proven go-to-market strategy, and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep.

At the core of Vivos’ mission to rid the world of mild-to-moderate OSA is the Vivos System®, a revolutionary clinical breakthrough in the treatment of mild-to-moderate sleep apnea often caused by craniofacial anatomy development. The Vivos System® multidisciplinary treatment protocol involves collaboration between physicians, specially-trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary health care providers.

In support of its growth strategy, Vivos has established contract manufacturing facilities in the U.S., Canada and Asia.

Market & Technology Overview

Craniofacial developmental deficiencies, such as underdeveloped upper and lower jaws, are among the leading causes of OSA. According to a 2019 analysis from researchers at the University of California, San Diego, an estimated 81 million adults in North and South America suffer from moderate to severe OSA. The United States has the highest amount of these patients, with approximately 54 million adults affected, according to the report.

Registered with the FDA as a Specification Developer, Vivos develops and markets a number of oral appliances. Its technology represents the first non-surgical, non-invasive and cost-effective treatment for the estimated hundreds of millions of people globally who suffer from mild-to-moderate OSA.

Vivos integrates its specially designed, customized appliances into a patient-specific, multi-disciplinary clinical protocol, giving trained dental and medical providers the tools and roadmap needed to address certain craniofacial conditions that studies have shown to be associated with sleep-disordered breathing—including mild-to-moderate OSA.

The system’s treatment protocol involves collaboration between physicians, specially trained dentists who have received advanced training in craniofacial sleep medicine, and additional health care providers. Vivos-trained clinicians can be found in almost every major city in the U.S. and in many countries throughout the world. The company’s oral appliances have shown to be effective in over 15,000 patients successfully treated worldwide by approximately 1,200 trained dentists.

A New Paradigm in Sleep Medicine

Vivos’ proprietary system poses the potential to be the biggest breakthrough in the treatment of mild-to-moderate OSA since CPAP.

The Vivos System has been specifically designed to promote the proper growth and development of the hard and soft tissues surrounding and comprising the oral cavity, nasal cavity, upper and lower jaws, and other tissues which together form and shape the upper airway. As these areas develop more fully using the Vivos System, a patient’s airway typically widens and expands, enabling them to breathe properly through their nose. With a more open and less obstructed airway, and easier nocturnal breathing, the symptoms of SDB tend to diminish over time, and patients often report they no longer suffer from the adverse effects of SDB or OSA.

Use of the Vivos System is variable and case dependent, but typically recommended to be worn daily for 12 to 16 hours starting in the early evening and continuing overnight. The total treatment time typically ranges from 12 to 24 months, with 18 months being the approximate mean treatment time.

Biomimetic Oral Appliance

Vivos Therapeutics believes that the Vivos System technology represents the first non-surgical, non-invasive and cost-effective treatment for people with mild-to-moderate OSA.

Combining technologies and protocols that can alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can significantly reduce symptoms and conditions associated with mild-to-moderate OSA.

The Vivos System treatment is typically less than $10,000 and is often reimbursable by medical insurance as an out-of-network benefit.

A potentially serious medical problem with an alternative treatment therapy available in the dental office.

Hard and soft tissues of the craniofacial complex can be non-surgically enhanced using the proprietary Vivos® System devices and clinical protocols.

Leadership

R. Kirk Huntsman – CEO, Director
With experience in strategic development, technology acquisition and product planning, key talent recruitment, and target market prioritization, Huntsman brings a broad vision paired with leadership and strategic planning skills. He has significant start-up experience in a diverse range of market sectors, including medical devices, dental management, dental practice valuations and transitions, multi-location retail, financial and capital formation, consulting, outsourced services, imports and exports (China), medical services, and software and technology.

Dr. Dave Singh – Founder, Director
A doctor three times over in dental medicine, craniofacial development, and orthodontics, Dr. Singh was educated primarily in England and has lectured in North America, Europe, Asia, and Africa. The Global Summits Institute recently named Dr. Singh as one of the Top 100 Doctors in Dentistry.

Vivos Therapeutics Inc. (NASDAQ: VVOS), closed Wednesday’s trading session at $4.29, even for the day, on 379,231 volume. The average volume for the last 3 months is 379,094 and the stock's 52-week low/high is $2.60999989/$14.4099998.

Recent News

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC)

The QualityStocks Daily Newsletter would like to spotlight AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC).

  • AnPac Bio’s clinical laboratories are located in the U.S. and China, with a total of 142 patents issued as of March 2021
  • Cancer Differentiation Analysis (“CDA”) technology is AnPac Bio’s approach to early cancer detection and screening technology, with over 200,000 samples and cases to serve as a way of approaching cancer screening
  • Company’s ownership percentage in subsidiary AnPai (Shanghai) Healthcare Management Consultant Co. Ltd. has increased from 20% to 60%, following rigorous regulatory assessments and audits

With a focus on early cancer screening and detection, biotechnology company AnPac Bio-Medical Science (NASDAQ: ANPC) recently announced that its U.S. laboratory has received accreditation from the College of American Pathologists (“CAP”). The U.S. federal government recognizes the CAP Laboratory Accreditation Program as equivalent to or more stringent than the government’s inspection program for laboratories. The accreditation from CAP is considered the gold standard for laboratories of this nature (https://ibn.fm/05KFN).

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection. The company develops, distributes and deploys accessible early disease detection devices with an aim of changing the way people approach cancer screening. AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance.

AnPac Bio-Medical has clinical laboratories in the United States and China, with 142 issued patents as of March 31, 2021. Its corporate headquarters is located in Shanghai, China, while its U.S. headquarters is situated in Philadelphia, Pennsylvania. The company operates two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States.

Cancer Differentiation Analysis (CDA)

Cancer Differentiation Analysis (CDA) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form.

Most liquid-based cancer screening and detection technologies focus on biochemical signals, like conventional biomarkers and genomic signals, such as ct-DNAs and CTCs (circulating tumor cells in the blood). These typically only determine whether or not cancer has occurred at a fixed point in time.

CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future – all through a standard blood test, at a competitive price point.

AnPac Bio-Medical’s CDA is powered by a database of over 200,000 samples and cases and serves as a new way to approach disease and cancer screening. The device uses an integrated system of sensors to detect several biophysical signals at the cellular, protein and molecular levels. CDA leverages a proprietary algorithm to synthesize the data, effectively generating a personalized risk assessment for evaluated patients.

Through CDA technology, AnPac Bio-Medical aims to address a number of goals, including:

  • Innovate – AnPac Bio-Medical is an innovator in the cancer screening industry, with CDA research ongoing since 2008, and commercial operations beginning in 2015. AnPac considers itself a thought leader in developing multi-cancer screening.
  • Detect – AnPac Bio-Medical detects early signals of threatening cancer and its location within the body.
  • Identify – CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity rates.
  • Provide – The company’s platform provides multi-level, multi-parameter analysis using proprietary diagnostic algorithms, which results in accurate and easy-to-understand results.
  • Proven – A fully operational analysis of over 200,000 test samples has been run to date. CDA technology has been shown to identify pre- and early-stage cancers in patients previously diagnosed as “cancer-free” through traditional methods.
  • Biophysical Properties – CDA analyzes biophysical properties in human blood and the correlation between biophysical properties and cancer occurrence.

Market Outlook

AnPac Bio-Medical is exploring detection of other types of cancers leveraging its innovative CDA technology and multi-cancer screening and detection tests, which could open significant opportunities on the global cancer diagnostics market.

According to a report by Grand View Research, the cancer diagnostics market is expected to reach $249.6 billion worldwide by 2026 (https://nnw.fm/L7css). The market is expected to grow at a CAGR of 7% during the forecast period.

Management Team

Dr. Chris Yu is the Co-Founder and Chief Executive Officer of AnPac Bio-Medical. He has enjoyed a successful career as an innovator in life sciences, technology and engineering. Dr. Yu has worked for three U.S. Fortune 500 companies and is the first/principal inventor of over 300 patent applications spanning semiconductors, materials and life science. He has a proven history of developing cutting-edge products with long-term profit and sustainability. Dr. Yu was born to a medical doctor’s family and went to medical school. He later switched his major to physics and received his bachelor’s and master’s degrees in physics from the University of Missouri-Kansas City Campus and a doctoral degree in physics from Pennsylvania State University. Both of his dissertations addressed innovative detection techniques.

Dr. Herbert Yu is the Co-Founder and Chief Medical Officer of AnPac Bio-Medical. He is a renowned expert in molecular epidemiology, with training in medicine and chemical biochemistry. Dr. Yu has a 20-year career in leading-edge cancer research, including breakthrough work in areas of carcinogenic factors. He is a professor and research director at the University of Hawaii and an adjunct professor at Yale University. He received his bachelor’s degree in medicine from Shanghai First Medical College. Dr. Yu also received a science degree in epidemiology and a Ph.D. in clinical biochemistry from the University of Toronto.

Jingiu (Edward) Tang is the company’s Chief Financial Officer. He previously served as a global internal auditor at Natuzzi S.p.A. Mr. Tang also worked at Beijing Dongshen CPA and Shanghai De’an CPA, providing external audits, finance and tax advisory services across different industries and sectors. He is a Certified Public Accountant in Australia. Mr. Tang received his bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University, and his bachelor’s degree in law from Southwest University of Science and Technology in China.

Weidong Dai is the company’s China General Manager. He previously served as a general partner at Stirrfir Investment Management Co. Mr. Dai has also served as the chairman of RTS Management (Shanghai) Co., and as managing director of Hong Kong Pro-Health Technology Co. and Shanghai Pro-Health Medical Devices Co. He has published a number of medical research papers and research articles in professional journals. Mr. Dai was awarded the Hong Kong Industrial Award for a medical device that he led in research and development. He earned his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from the Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics.

AnPac Bio-Medical Science Co. Ltd. (ANPC), closed Wednesday’s trading session at $3.96, up 11.236%, on 1,969,309 volume. The average volume for the last 3 months is 1.945M and the stock's 52-week low/high is $3.15000009/$12.0900001.

Recent News

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF)

The QualityStocks Daily Newsletter would like to spotlight Avricore Health Inc. (OTCQB: AVCRF).

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) is disrupting and revolutionizing the pharmacy practice through its proprietary HealthTab(TM) solution, which sources the best point-of-care analyzers and brings them into a single, secure cloud-based network. A recent article quotes Avricore CEO Hector Bremner as saying, “The power of HealthTab is that it is able to greatly reduce the amount of administration time, extract the results directly out of the machine, merge information, do the complex calculations in order to properly interpret the data, and then produce it in an easy to read format that the patient and professional can interpret quickly and understand the result and then use that to guide their care plan.” HealthTab also boasts a de-identified real-time data attribute that can enable researchers, drug makers, governments and NGOs to use the platform to conduct studies and research in real-time, real-world settings in community pharmacies. Further, “Built on an open API platform, HealthTab can connect to other B2B or B2C health data-focused software. As a result, the platform, which supports easy and quick data transfers, can power third-part health tech products with real-world results and direct diagnostics from pharmacies.” To view the full article, visit https://ibn.fm/dJjJw

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab™ (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

HealthTab

HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets and third-party app integration through API.

Agreement with Shoppers Drug Mart

In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2™ analyzers provided by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near Term Goals

Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies.

Market Outlook

In 2020, the global point-of-care testing (POCT) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (CAGR) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Management Team

Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia.

Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia.

Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Avricore Health Inc. (OTCQB: AVCRF), closed Wednesday’s trading session at $0.1299, even for the day, on 60 volume. The average volume for the last 3 months is 60 and the stock's 52-week low/high is $0.035/$0.485619992.

Recent News

ISW Holdings Inc. (OTC: ISWH)

The QualityStocks Daily Newsletter would like to spotlight ISW Holdings Inc. (OTC: ISWH).

ISW Holdings (OTC: ISWH) (transitioning to “BlockQuarry,” pending name change), a Nevada-based portfolio company with primary commercial-stage operations in cryptocurrency mining, released an update to current and prospective shareholders on core performance metrics, timeframe for hosting deployment and corporate identity. Among the highlights, the company indicated that mining is fully underway in Pennsylvania, nearing full capacity on hashrate, and final adjustments and updates are being implemented into month end to push performance up to peak potential. The company anticipates a record quarter for the three months ending Sept. 30, 2021. In addition, ISWH expects and a much more significant breakout in financial terms in the fourth quarter after a full three months of mining at peak capacity as well as the start of revenues from hosting operations. “We will unquestionably log our best quarter in company history — by a wide margin — when the books close at the end of the month,” said Alonzo Pierce, ISWH CEO. “But that will likely be dwarfed by what rolls in over coming quarters. We have made a few final adjustments and updates that are being implemented right now that will take us to full capacity in terms of achievable hashrate in Pennsylvania. That will bring us to a topline run-rate of approximately $1.5 million per month, which may double again beginning midway through the fourth quarter as we begin to ramp up hosting revenues.” To view the full press release, visit https://ibn.fm/1AEaL

ISW Holdings Inc. (OTC: ISWH), through its in-house initiatives and strategic partnerships, has invested in growing operations targeting the telehealth and cryptocurrency mining industries.

The company specializes in strategic brand development and early growth facilitation. Management maneuvers its proprietary companies through critical stages of market development, including conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency.

Mission

The company’s core mission is to enhance these sectors by implementing innovative services and products that are ready to meet the demands of a changing world. To that end, ISW Holdings leverages its strategic expertise, resources and innovative software to establish market-leading companies and partnerships, thereby ensuring success in their chosen industries.

Cryptocurrency Mining

The start of 2021 saw a massive resurgence in interest surrounding bitcoin and cryptocurrency mining. In mid-February, bitcoin prices hit an all-time high of greater than $57,000, and heightened demand for cryptocurrency mining power has played a key role in exacerbating a global shortage of semiconductors and computer components.

With a foothold in the cryptocurrency mining space, ISW Holdings has placed significant focus on expanding its position and capitalizing on this momentum. Recent highlights include:

  • February 9, 2021: The company announced that its revolutionary Pod5 Cryptocurrency Mining Pod will be powered up into full operational launch at the Bit5ive renewable energy cryptocurrency mining facility in Pennsylvania on February 12, 2021.
  • February 11, 2021: The company announced that it is in negotiations to purchase a large number of miners (between 300 and 900) in preparation for its coming Phase 3 expansion in mining volume.
  • February 23, 2021: The company announced its entry into a comprehensive Hosting and Maintenance Agreement prior to going online with its new ASIC s17 miners.
  • March 2, 2021: The company announced that it has successfully tripled its active cryptocurrency mining fleet with the addition of two new POD5IVE datacenters.

“As we continue to bring our miners online, we want our shareholders to be able to track the expansion and profitability of the company’s mining activity given the sharp rising trend in bitcoin prices,” Alonzo Pierce, President and Chairman of ISW Holdings, stated in a news release. “It currently costs about $11K in computing power to mine a single bitcoin. Bitcoin is pricing at over five times that level, making this is an exceptional ROI opportunity, and our responsibility to our shareholders is clear: continue to invest, expand and execute.”

Business Innovations

ISW Holdings’ diverse portfolio reflects the growing demand for essential services in a dynamic modern operational landscape. Some of the company’s current holdings and partnerships include:

  • Bit5ive LLC: ISW Holdings operates a joint venture with Bit5ive, a global leader in cryptocurrency mining. The joint-venture agreement enables ISW Holdings to collaborate with the experienced team at Bit5ive to innovate the infrastructure needed to run profitable and efficient crypto mining projects.
  • Proceso LLC: ISW Holdings has partnered with Proceso LLC to create high-density processing and mobile data centers powered by renewable energy. These innovations will allow Proceso to offer lower-cost and diverse services to its clients, including hosting and colocation services to growing sectors such as the gaming industry and cryptocurrency mining.
  • PHH Health: The company’s home health division answers the growing need for home care services in a world where health care delivery is changing and an increasingly large aging community is looking for efficient and effective ways of accessing health care.
  • Volum: The company’s logistics and supply chain management division is designed with the core goal of increasing supply chain efficiency, which is recognized as one of the key aspects of successfully growing any business.

Market Opportunity

ISW Holdings’ recent activity in the cryptocurrency mining sector has positioned it to capitalize on the forecast expansion of the cryptocurrency market in the coming years. According to data from MarketsandMarkets, the cryptocurrency space was valued at $1.03 billion in 2019 and is projected to reach $1.40 billion in 2024, achieving a CAGR of 6.18% during the forecast period.

The report suggests that major drivers for this growth will be the transparency of the underlying blockchain technology, the high volume of remittances in developing countries, the high cost of international remittance, expected fluctuations in monetary regulations and sustained investment in the cryptocurrency space by venture capital firms.

Management Team

Terry Williams is the Chief Executive Officer and Director of ISW Holdings. Mr. Williams brings to the company more than 30 years of experience in accounting and information systems, logistics, insurance and transportation. With a Bachelor’s and Master’s degree in accounting and management information systems, he amassed considerable corporate experience at UPS (NYSE: UPS), where he took several logistical roles, managing more than 2,000 employees and a budget of more than $10 billion. Mr. Williams also serves as president of Airware Transportation and Logistics and Chief Financial Officer of AVI Insurance Caribbean. In 2013, he received the National Airport Minority Advisory Council Award for mastering skills in the aviation industry.

Alonzo Pierce is the company’s President and Chairman. He brings a wealth of business development and wealth management experience to the ISW team, having spent the past 20 years building recognizable brands in multiple industry sectors. Mr. Pierce has launched enterprises in life-styled brands which were delivered to high-profile, high-net worth families and individuals. He has worked in the adult beverage industry, establishing a formidable background in marketing and brand creation. Pierce has a B.A. from Baylor University and has received multiple awards in the adult beverage industry, including ‘Outstanding Sales Performance in the Southern Region’ for Sapphire Brands. Pierce also served as a national liaison to a Super-Regional Bank’s private wealth division. In addition to his for-profit endeavors, Pierce has served on multiple charitable boards, sourcing funding for JRA, food insecure families and housing insecure families.

Kristina Mahoney-Brown is Secretary, Treasurer and Director of ISW Holdings. With more than 20 years of experience providing tax and financial consulting to real estate companies, as well as investors, developers and construction companies, Ms. Mahoney-Brown has gained solid business expertise and market knowledge and prides herself on staying abreast of the latest industry trends. Her professionalism, impeccable work ethic and advanced marketing strategies have earned her the nickname ‘The Tax Diva’. Mahoney-Brown has a Bachelor’s in accounting, a Master’s in taxation and a Master’s in business administration, specializing in personal financial planning.

ISW Holdings Inc. (ISWH), closed Wednesday’s trading session at $3.52, up 14.658%, on 2,711,667 volume. The average volume for the last 3 months is 2.711M and the stock's 52-week low/high is $0.0152/$3.5999999.

Recent News

Tingo Inc. (OTCQB: IWBB)

The QualityStocks Daily Newsletter would like to spotlight Tingo Inc. (IWBB).

Not often does a company gain entry to the billion-dollar club. However, technology and communications pioneer Tingo (OTCQB: IWBB) just did it – twice.  Shortly after going public in a deal valued at $3.7 billion, Tingo rang the billion-dollar bell a second time with its acceptance into IBN’s Billion Dollar Club. This powerful adjunct program created exclusively for IBN CORE Client Partners gives Tingo personal access to Oren Klaff, best-selling author and world-renowned expert on sales, revenue acceleration and high-stakes negotiations. Tingo Inc, OTC Markets (IWBB), announced the appointment of John J. Brown and Christophe Francois Charlier as Co-Chair to add global market experience to its already strong Board of Directors and further support the Company's application to list its shares on a national securities exchange such as the New York Stock Exchange. John Brown , age 63, is the independent co-Chair of the Company. Since 2016, John has also been the Managing Partner of Sands Point Consulting LLC, an advisor to entrepreneurs, founders, and senior corporate leaders to develop new business strategies for a rapidly changing market. From 2009-2016, he was the Group Managing Director and a member of the WMA Executive Committee for UBS Wealth Management Americas, successfully executing a five-year cross-divisional business strategy to return UBS WMA to sustainable profitability. From 1995-2000, John was the Managing Director and Global Head of Convertible Securities Trading at UBS, and from 1980-1995 and again from 2000-2009 he was a Managing Director for Merrill Lynch & Co., holding senior executive leadership positions at Merrill Lynch, most notably COO, Operations, Technology & Corp. Services Group. At Merrill Lynch, He also served as the Head of US Equity Financing & CEO, Merrill Lynch Professional Clearing Corp in its Prime Broker Division. He oversaw the exponential growth in hedge fund and professional trading client base assets.

Tingo Inc. (OTCQB: IWBB) is a digital service agri-fintech technology company focused on foundation-level agriculture and related financial services in Africa. The company aims to be Africa’s leading agri-fintech player, transforming rural farming communities to connect through its proprietary platform to meet their complete needs – from inputs and agronomy to off take and marketplace – and deliver sustainable income in an impactful way. The company’s vision is to build complete digitally inclusive ecosystems that promote financial inclusion and deliver disruptive micro-finance solutions, empower societies, produce social upliftment in rural communities and open international opportunities.

Tingo believes that a truly connected world will help contribute to a better global society. The company’s core focus areas are telecoms, financial services/fintech and agritech. Tingo’s goal is to provide a best-in-class customer experience, support the domestic economies of its host countries and support technological and financial inclusion to end the poverty premium. Through this, Tingo hopes to deliver attractive returns to shareholders while investing in the long-term future of the company and its subsidiaries.

Global climate change is challenging sustainable production and food security. Tingo’s strategy and market execution provide an opportunity for Africa to be a core focal point to solve a number of key areas of concern, including food security, gender equality, financial inclusion and poverty alleviation, to name a few. Disruption of micro finance through the use of DeFi-based stable coins and smart contracts will give agri-communities access to capital markets-driven digital finance solutions that make them more competitive and sustainable economically, striking a good balance of returns between digital asset providers and Tingo as the service partner. This innovation will deliver significant access to much needed finance at ‘Grassroot’ levels, delivering tangible social upliftment and GDP growth in the African markets served by Tingo.

Tingo Mobile, with more than nine million subscribers, is Nigeria’s leading technology and device-as-a-service platform aimed at accelerating digital commerce, especially in the country’s agritech and fintech verticals. The company helps farmers acquire mobile phones through a unique leasing plan, connecting them to mobile and data networks through its own virtual mobile network. Tingo also connects farmers to markets, services and resources via Nwassa, its digital agritech marketplace platform that commenced operations in 2020. The company has also launched a beta version of TingoPay – a B2B and B2C fintech app aimed at providing financial services to users inside and outside of the agriculture value chain. Among the services offered are mobile wallets, payment processing and access to specialist lenders, insurers and pension products.

Tingo will soon announce its innovative blockchain-based solution for use of digital stable coins to empower frictionless trade across borders in Africa. The company’s market-proven model in Nigeria is its core foundation, enabling Tingo to deliver the same service model across Africa to become the continent’s leading agri-fintech business powered through smartphone technology.

The African Continental Free Trade (ACFT) plan will be a key framework to prepare the company to be the leading intra-Africa trading hub for trade flows across Africa in the medium term, when it is likely the agreement will be executed into tangible activity. Tingo is well positioned to easily transform the goals of the ACFT into reality when finally implemented by the African Union and the various African countries that have not signed up.

Tingo posted total revenue of $594 million in 2020, with $212 million EBITDA. As of December 31, 2020, Tingo has 9,344,000 subscribers. The company is confident that these figures will grow through its expansion across Africa and natural progression of business in Nigeria.

Businesses

Tingo has four core businesses:

  • Mobile Phone Leasing – Tingo has distributed almost 30 million mobile handsets since 2014 and will continue to replace the devices of its installed customer base every three years. Tingo Mobile provides the latest mobile phone handsets at an affordable price point and allows customers to spread payments over 36 months.
  • Mobile Voice and Data Service – Through a mobile virtual network, Tingo provides its customers with voice and data services, allowing customers to communicate effectively, both inside and outside the agricultural ecosystem.
  • Nwassa Marketplace Platform – Nwassa is Tingo’s proprietary agritech platform which provides Africa’s farmers with access to global markets to secure more competitive pricing for their crops. The platform processes 500,000 daily transactions with a value of over $8 million. A select group of trusted partners can assist smallholder farmers and agricultural cooperatives with packaging, warehousing, and dry and wet cargo logistics, as well as up-to-date information from the global agricultural sector. Tingo provides its customers with digital wallet services, which enable them to send and receive domestic payments, monitor cash flow in real time and securely hold money. The company also provides access to other services, such as utility bill payment, virtual airtime top-up, insurance services and alternative lending solutions.
  • TingoPay – Since the launch of the Nwassa platform, Tingo has been a dominant player in the B2B fintech vertical. After many successful months of operating Nwassa, Tingo entered the fintech B2C vertical to extend its B2B offering to a broader market beyond agriculture.

TingoPay is still in its beta phase and will launch in 2021 with a comprehensive marketing campaign. TingoPay offers the following services:

  • Tingo Wallet top-up
  • Peer to Peer payments, inclusive of merchant payments at the stores
  • Utility payments – airtime, broadband, cable, electricity, water, hotel, flights etc.
  • Pension payments
  • QR code payment services

Market Opportunity

Africa is the second-largest continent by population. It is also the youngest by far, with a median age of 18 for its 1.3 billion people. Tingo believes the building blocks for growth in Africa’s agriculture industry are in place and that the company is well positioned to participate in the upside. Sub-Saharan Africa’s population is growing at a rate of 2.7 percent per year. At the current growth rate, the continent’s population will double by 2050. Africa’s youthfulness represents a significant opportunity for material growth in demand for agricultural commodities. This younger generation is also being born into a digital world and is comfortable using technology.

Africa’s governments are improving business conditions for entrepreneurs and small businesses. Sub-Saharan Africa’s World Bank Doing Business rank has improved from 45 in 2004 to 65 in 2020. Tingo believes this trend will continue and encourage establishment of more new ventures across all economic sectors, including agriculture.

Africa attracted $407 billion of Foreign Direct Investments (“FDI”) between 2014 and 2018. Investments are increasingly focused on services and industrial sectors. Only 20 percent of investments are in extractive industries – a clear reversal from 2008, when 55 percent of FDI was aimed at resource extraction. Tingo believes FDI into Africa will help resolve significant infrastructure constraints and create value for agribusiness.

Management Team

Dozy Mmobuosi is the CEO of Tingo. He cofounded Tingo Mobile PLC (Nigeria) in 2001 and led the design and launch of Nigeria’s first SMS banking solution, which is still in use in the country today. He also headed a team of more than 120 Chinese and Nigerian engineers in the construction of two mobile phone assembly plants in Nigeria, which have produced and distributed 20 million phones across the country. He has led Tingo’s growth to more than $600 million in revenue annually. He holds a Ph.D. in Rural Advancement from UPM Malaysia.

Dakshesh Patel is the CFO of Tingo. He was formerly CFO of NatWest’s Global Debt and Investment Banking division. He has served as a Director at Gerken Capital Associates, a San Francisco-based alternative asset fund manager. He also led the restructure of Lloyds Banking Group (last financial crisis); managed integration of two leading shipping groups’ global treasury function to create world-leading shipping group Maersk Shipping; built three fintech companies; and exited one to Worldpay. Mr. Patel has strong banking experience, with a focus on Africa. He is a chartered accountant.

Chris Cleverly is president of Tingo. He has served as CEO of the Made in Africa Foundation, and as CEO of blockchain payments gateway startup Kamari. He has been a board member of several companies, both public and private, in the UK, India, China and Africa. He has advised multiple UK companies on their entrance into African markets, and regularly advises the UK Government on development issues and African governments on investment issues.

Clarence Simms is the Chief Technology Officer at Tingo. He has 25 years of IT and IT management experience. He has worked in IT Shared Services Technical Operations and IT Program Management for Huawei Technologies and MTN. As an entrepreneur, he created Africaprepay.com, a service that allows African Diaspora travelers to send airtime, pay bills, send mobile money and transfer money to a bank account from anyplace in the world.

Rory Bowen is the Chief of Staff at Tingo. Mr. Bowen started his career in traditional capital and derivatives markets working for Moneycorp and Tradition UK in European and emerging markets across FX, interest rate derivative and government bond markets. He has also spent time with one of Europe’s fastest growing fintech’s banking circles. Before joining Tingo, he was Chief of Staff at FinTech Alliance, an organization established in partnership with the UK Government Department for International Trade to foster innovation, growth and foreign direct investment (FDI) in the financial services sector and facilitate greater public/private cooperation.

Tingo Inc. (OTCQB: IWBB), closed Wednesday’s trading session at $1.75, off by 9.3264%, on 4,290 volume. The average volume for the last 3 months is 4,290 and the stock's 52-week low/high is $1.50/$8.97999954.

Recent News

RYAH Group Inc. (CSE: RYAH)

The QualityStocks Daily Newsletter would like to spotlight RYAH Group Inc. (CSE: RYAH).

RYAH Group (CSE: RYAH) today announced that its Chief Executive Officer Gregory Wagner will be presenting at Wall Street Reporter's "Next Super Stock" livestream conference on Thursday, Sept. 23, 2021. The online event is expected to give the investment community and existing shareholders an opportunity to interact in real time with Wagner and learn about the company and its operations. Wagner’s presentation is scheduled to begin at 1:00 ET on the day of the conference, during which he will highlight RYAH’s experience and mission, and, time permitting, open the floor for questions. Interested parties should visit https://ibn.fm/K0MtA to ensure access to attend the livestream conference and receive any updates. An archived webcast will be made available after the conference for those not able to join the live event. To view the full press release, visit https://ibn.fm/4yT8a

RYAH Group Inc. (CSE: RYAH) is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions.

The company is a leading developer of dose-measuring IoT devices connected with its turn-key platform designed to aggregate and correlate HIPPA-compliant data, suitable to all participants in the patient treatment cycle. The company also specializes in customized, fully integrated, mobile applications and APIs, specifically designed to meet the needs of clinics, clinical trials, government and university research centers, for experimentation and treatment validation – significantly reducing variations in patient-related trials. RYAH unlocks data in the complete therapeutic plant lifecycle – from seed to consumption.

Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed to capture anonymous patient dosing and feedback, combined with detailed strain analytics, enabling customized dosing regiments. The company has secured numerous partnerships across the globe, including establishing a footprint in the UK, USA, Australia and Canada, and it has closed several deals in the European Union, as well. The company’s Smart-Inhaler has been selected as the dose-measurement, dose-control and data analytics platform for a UK pain management study and one of the world’s most ambitious and largest clinical trials ever to be conducted in cannabis.

Product Portfolio

The company’s current portfolio incorporates an ecosystem of IoT products, each consisting of three elements: the device, the medicine-carrying component and the mobile application. The product line currently includes a Smart Dry-Herb Dose-Measuring Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage and a Smart Liquid Dispensing Pen in the prototype stage.

RYAH Smart-Inhaler

The RYAH Inhaler is the first dry-herb inhaler that allows users to track and control how much is inhaled, providing consistent and predictable results. This inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and dosages, all of which can be customized to individual needs and doctor recommendations, as well as a post-session review mechanism that allows the collection of session data and feedback for further efficacy analysis for customized dosing capabilities.

RYAH’s proprietary stainless-steel cartridges for the inhaler use QR technology that contains lab testing and grower information pertaining to the specific strain, thereby mitigating elicit product use and enabling completely transparent remote medicinal analytics, from seed to consumption.

In addition, the RYAH Cartridges provide a unique closed-loop recurring revenue opportunity for the company, as the RYAH Inhaler only works with this type of proprietary cartridges that licensed partners fill with medicine. The partners benefit from all the back-end data, providing them access to consumption habits, statistics and other data on patient preferences.

RYAH Smart-Patch

The RYAH Smart Transdermal Patch is a lightweight, reusable, mobile-controlled patch used for site-specific therapies. The Patch is an Electronic Topical Delivery Patch system intended for recommendation and administration by pain relief professionals and physical and occupational therapists. The patch data and the heating element is completely IoT and controlled by RYAH’s proprietary smartphone applications, which allows scheduling and ‘boosting’ medicine release, on-demand.

RYAH Smart-Pen

The RYAH Pen is an app-controlled liquid dispenser designed to provide a precise mix of up to three medicine components to create an ‘entourage effect’, enabling customized, wide-spectrum recommendation opportunities by licensed clinicians. The Smart-Pen will feature cartridges that contain CBD, THC and other isolates such as flavonoids or vitamins, or other solutions. There is a built-in mechanism designed to control usage based on recommended dosing schedules.

RYAH MD

RYAH MD serves as a remote and interactive patient-doctor collaboration and dosing administration platform. Doctors can remotely set dosage amounts for their patients, creating digital prescriptions for the RYAH IoT devices and tracking patient usage in real-time. RYAH MD offers features that include real-time monitoring, appointment booking, doctor-patient video calls and science-based strain recommendations, as well as promoting a better understanding of the effects and benefits of those recommendations among patients. Information is gathered from all of the RYAH devices.

PotBot App

The PotBot App is a medical cannabis education mobile application that leverages patented AI technology to capture structured and unstructured data to assist patients in learning about various treatments in plant-medicine based on their efficacy goals. The PotBot App is currently one of the top-rated medical cannabis educational mobile applications on the Apple App Store in the United States, with over 300,000 downloads.

Through the combination of peer-reviewed and empirical data, the PotBot App provides detailed information on the targeted and tested cannabinoid levels and associated strains from cannabis patients. The result is personalized and driven by data to inform patients of potential product matches associated with similar ailments and efficacy goals.

Market Outlook

RYAH holds a unique position in the $100.3 billion medical plant market, with the potential to capture and capitalize on growth opportunities made available by both the IoT and Data Intelligence sectors.

In 2018, the global IoT market was valued at $212.1 billion, and it is expected to grow exponentially to $1.3 trillion by 2026, registering a CAGR of 25.68%, according to Verified Market Research (https://ibn.fm/XtkPZ).

Management Team

Dr. Boris Goldstein, Ph.D., is the founder and Chairman of RYAH Group. He is a seasoned entrepreneur, investment banker and venture capitalist. He started his career as the founder of Software House HT, which grew into a worldwide corporation with over 40 offices in 17 countries. Since then, Goldstein has founded and served on the boards of directors and advisory boards for numerous companies in Silicon Valley and Silicon Alley. Goldstein brings experience in fundamental research, investment and technology, authoring multiple patents and books.

Gregory Wagner, MBA, is Chief Executive Officer and Director of RYAH Group. He has over 20 years of experience in global financial markets and entrepreneurship. Wagner has held executive roles in the United States and London. He has co-founded and built several startups from the ground up. His current licensures and degrees include FINRA Series 7, 63, 24 and 55, as well as an MBA from Fordham University. Wagner received a Certification in Innovation and Strategy from Harvard University.

RYAH Group Inc. (CSE: RYAH), closed Wednesday’s trading session at $0.14, up 27.27%. The average volume for the last 3 months is 590,071 and the stock's 52-week low/high is $0.055/$0.20.

Recent News

FingerMotion Inc. (OTCQX: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (OTCQX: FNGR) .

  • A 2020 Deloitte China report noted that big data will be vital in ensuring insurance survive for longer post-pandemic and accelerate their transformation towards excellence 
  • Big data is instrumental in facilitating greater product innovation and pricing accuracy for insurers
  • Through its Big Data Insights division (Sapientus), FingerMotion appears well positioned as an ideal partner for insurers looking to implement Deloitte’s proposals
  • The China Banking and Insurance Regulatory Commission recently scrapped the 51% cap on foreign ownership, setting the stage for potential growth of the country’s insurance sector

Last year, Deloitte China released a report titled “COVID-19 and China’s Insurance Industry” that explored the measures insurers have taken to deal with the pandemic, the macro impact of COVID-19 on the insurance industry, and, lastly, how insurance companies should accelerate their transformation towards excellence (https://ibn.fm/U2kpn). The report noted that big data, which some insurers were already using as early as February 2020, will be instrumental in the post-pandemic insurance world. According to Deloitte China, the pandemic posed a significant challenge to the adaptability and resilience of insurance companies and their management teams. This means that these firms need to consider building sustainable management systems to ensure longevity moving forward. The report proposed that insurers should apply big data to facilitate product differentiation and build digital operational capabilities. With mechanisms already in place, having launched its Big Data Insights division (Sapientus) in July 2020 and subsequently partnered with Pacific Life Re-Insurance, evolving technology company FingerMotion (OTCQX: FNGR) appears poised as an ideal partner for insurers looking to implement Deloitte China’s proposals. 

FingerMotion Inc. (OTCQX: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Wednesday’s trading session at $4.5, up 3.6866%, on 27,114 volume. The average volume for the last 3 months is 27,114 and the stock's 52-week low/high is $2.35999989/$17.00.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading